[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07095686":3,"trial-entities:NCT07095686":93,"trial-summary:NCT07095686":97},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":15,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":21,"phases":22,"enrollment_info":25,"interventions":28,"primary_outcomes":35,"secondary_outcomes":51,"sex":65,"minimum_age":66,"maximum_age":15,"healthy_volunteers":67,"eligibility_criteria":68,"std_ages":77,"locations":80,"central_contacts":89,"overall_officials":90,"references":91,"see_also_links":92},"NCT07095686","AAAV3923","Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS","An Open-Label Study of an Experimental Antisense Oligonucleotide Treatment for Amyotrophic Lateral Sclerosis (ALS) Due to an Arg15Leu Pathogenic Variant in CHCHD10","ENROLLING_BY_INVITATION","2027-04","2026-07","2026-07-13","2024-10-02","n-Lorem Foundation","OTHER",null,"This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for individual participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10",[18],"Amyotrophic Lateral Sclerosis",[],"INTERVENTIONAL","TREATMENT",[23,24],"PHASE1","PHASE2",{"count":26,"type":27},9,"ESTIMATED",[29],{"type":30,"name":31,"description":32,"armGroupLabels":33},"DRUG","nL-CHCHD-001","Personalized antisense oligonucleotide",[34],"Open Label nL-CHCHD-001",[36,40,43,45,47,49],{"measure":37,"description":38,"timeFrame":39},"Clinical Functioning","Change from baseline at 12-months post nL-CHCHD-001 administration in scores on Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R).","Baseline to 12 months",{"measure":41,"description":42,"timeFrame":39},"Motor Function","Change from baseline at 12-months post nL-CHCHD-001 administration in Slow Vital Capacity (SVC)",{"measure":41,"description":44,"timeFrame":39},"Change from baseline at 12-months post nL-CHCHD-001 administration in muscle strength as quantified by Handheld Dynamometry (HHD)",{"measure":37,"description":46,"timeFrame":39},"Change from baseline at 12-months post nL-CHCHD-001 administration in Edinburgh Cognitive and Behavioral ALS Screen (ECAS) score",{"measure":37,"description":48,"timeFrame":39},"Change from baseline at 12-months post nL-CHCHD-001 administration in scores on ALS Cognitive Behavioral Screen (ALS-CBS)",{"measure":37,"description":50,"timeFrame":39},"Change from baseline at 12-months post nL-CHCHD-001 administration in scores on Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5)",[52,55,58,61,63],{"measure":53,"description":54,"timeFrame":39},"Disease Biomarkers","Change from baseline at 12-months post nL-CHCHD-001 administration in serum and CSF neurofilament light chain levels",{"measure":56,"description":57,"timeFrame":39},"Safety and Tolerability","Incidence and severity of Adverse Events",{"measure":59,"description":60,"timeFrame":39},"Safety and tolerability","Emergent abnormalities in physical exam (changes in appearance, skin, neck, ears, nose, throat, heart\u002Flungs, abdomen, lymph nodes, and extremities compared to baseline)",{"measure":56,"description":62,"timeFrame":39},"Emergent abnormalities in neurological exam (changes in mental status, gait, cerebellar, cranial nerve, motor, reflex, and sensations compared to baseline)",{"measure":59,"description":64,"timeFrame":39},"Emergent abnormalities in laboratory analyses (results outside of normal range for CSF, chemistry, hematology, coagulation, and urinalysis)","ALL","18 Years",false,{"inclusion":69,"exclusion":73,"raw_text":76},[70,71,72],"Informed consent\u002Fassent provided by the participant (when appropriate), and\u002For participant's parent(s) or legally authorized representatives(s)","Ability to travel to the study site and adhere to study related follow-up examinations and\u002For procedures and provide access to participant's medical records","Genetically confirmed neurological disorder",[74,75],"Participant has any condition that in the opinion of the Site Investigator would ultimately prevent the completion of study procedures","Use of an investigational medication within less than 5 half-lives of the drug at enrollment","Inclusion Criteria:\n\n* Informed consent\u002Fassent provided by the participant (when appropriate), and\u002For participant's parent(s) or legally authorized representatives(s)\n* Ability to travel to the study site and adhere to study related follow-up examinations and\u002For procedures and provide access to participant's medical records\n* Genetically confirmed neurological disorder\n\nExclusion Criteria:\n\n* Participant has any condition that in the opinion of the Site Investigator would ultimately prevent the completion of study procedures\n* Use of an investigational medication within less than 5 half-lives of the drug at enrollment",[78,79],"ADULT","OLDER_ADULT",[81],{"facility":82,"city":83,"state":83,"zip":84,"country":85,"geoPoint":86},"Columbia University, Irving Medical Center","New York","10032","United States",{"lat":87,"lon":88},40.71427,-74.00597,[],[],[],[],{"nct_id":4,"conditions":94,"biomarkers":95},[18],[96],"COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING PROTEIN 10",{"nct_id":4,"found":67,"summary":15,"prompt_version":15}]